MTOR and mesothelioma: The PI3K/mTOR pathway is also highly activated in mesothelioma, but not in non-malignant mesothelial cells (Zhou et al., 2014) or adjacent tissue (Hoda et al., 2011), and phospho-mTOR was significantly associated with poorer overall survival in a cohort of 107 mesothelioma patients (Bitanihirwe et al., 2014).